Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics
For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh
Read moreFor our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh
Read moreRevive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms.
Read moreRevive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The
Read moreRevive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three clinical trials for the evaluation
Read moreThis morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn Life Sciences Inc. (CSE : HAVN) to source
Read moreThis morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical sites in Florida, Texas and
Read moreRevive Therapeutics (CSE: RVV) this morning announced that it has received approval from the Independent Institutional Review Board (IRB) for
Read moreRevive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this morning that it has entered
Read moreRevive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials for the use of Bucillamine
Read moreThis morning Revive Therapeutics (CSE: RVV, USA: RVVTF) announced they have submitted a clinical trial protocol to their independent Institutional
Read more